TOTUM-63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial.
Pascal SirventVivien ChavanelleYolanda F OteroMaxime BargettoFlorian Le JoubiouxNathalie BoisseauThierry MaugardMurielle CazaubielBruno PereiraBruno GuigasSamy HadjadjSebastien L PeltierAndré MaretteJean-Marie BardPublished in: Diabetes, obesity & metabolism (2022)
TOTUM-63 lowered fasting blood glucose in participants with impaired fasting glycaemia and glucose intolerance. Moreover, TOTUM-63 showed a good safety and tolerability profile and improved several metabolic syndrome features. Therefore, TOTUM-63 is a promising candidate for T2D prevention.
Keyphrases
- blood glucose
- double blind
- type diabetes
- glycemic control
- newly diagnosed
- early stage
- placebo controlled
- metabolic syndrome
- clinical trial
- insulin resistance
- phase ii
- phase iii
- study protocol
- oxidative stress
- blood pressure
- open label
- uric acid
- cardiovascular disease
- sentinel lymph node
- squamous cell carcinoma
- adipose tissue
- skeletal muscle
- neoadjuvant chemotherapy